Hypha Discovery

Hypha Discovery is a specialized CRO founded in 2008, serving as a trusted partner for metabolite solutions in drug and agrochemical development. Its core expertise lies in synthesizing, purifying, and definitively identifying difficult-to-make metabolites using an integrated platform of chemical synthesis, mammalian/microbial biotransformation, and recombinant enzyme technologies. The company generates revenue through fee-for-service contracts and the sale of its proprietary metabolite production kits (e.g., PolyCYPs, PolyUGTs) to enable in-house metabolite generation for clients. With a focus on supporting regulatory submissions and late-stage development, Hypha operates as a private, revenue-generating service provider in the biotechnology ecosystem.

Integrated platform combining chemical synthesis, mammalian/microbial biotransformation, recombinant human enzymes (PolyCYPs, PolyUGTs), and advanced purification/NMR spectroscopy for metabolite identification and synthesis.

Hypha competes with large CROs offering broad ADME services (e.g., LabCorp, Charles River) and smaller niche metabolite specialists. Its key differentiator is the integrated synthesis-platform, particularly the proprietary recombinant enzyme kits and deep expertise in difficult microbial biotransformation and definitive NMR structure elucidation.